hotspot -WSS

hotspot

author：explore 2025-10-02 03:24:26 - browse：2

illustration of a colorful DNA strand, partly broken into pieces. -- health coverage from STAT — Adobe

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells. If the patient ever stops taking medicines, those cells start pumping out HIV particles and the infection roars back.

Researchers hoped they could send CRISPR to those cells and, by cutting the HIV DNA lurking there at two spots, slice out the virus. In the Phase 1 trial, investigators administered the treatment to five patients. They then took three of them off conventional antiviral treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： New details revealed about Purdue's marketing of OxyContin

WSS

Humana cuts profit projections as Medicare Advantage costs soar

The tragedy of Johnson & Johnson’s Covid vaccine

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

The pain doctors face in trying to build their families

Eli Lilly, Pfizer, and others want in on the online prescription market

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Medical records are filled with copy

AI generated plenty of interest at JPM but not a lot of trust

Sports medicine is finally prioritizing gender equality

New details revealed about Purdue's marketing of OxyContin

Moonlake's readout produced a cash windfall. Risks remain

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Continuity nursing helped my family in our darkest PICU moments

FDA approves first treatment for ultra

The high cost of giving birth even with insurance

Congress must give Medicare recipients genetic counseling access

Wikipedia

ActiGraph execs on goal of drug approvals with digital endpoints

Research misconduct: Proposed new rules face resistance

Clinical trials must include more disabled people

Evacuations in place as 3 wildfires burn in eastern Washington state

Congress must give Medicare recipients genetic counseling access

The pain doctors face in trying to build their families

focus

focus

focus

leisure time